Biosimilar Introduction Reduces Biologic Prices in the US and Globally


After a biosimilar introduction, the prices of the biologic products—namely, trastuzumab, infliximab, bevacizumab, adalimumab, filgrastim, and pegfilgrastim—were significantly reduced.

Biosimilar Introduction Reduces Biologic Price in US and Globally

Hui-Han Chen, MHS, BS

Credit: UNC Eshelman School of Pharmacy

The price of biologics both globally and in the US significantly reduced following the introduction of biosimilars, a study found.1

Prior research showed biologics prices reduced after introducing biosimilars in the market.2 However, the studies analyzed this with insurance claims data, failing to show negotiations and discounts between healthcare providers and insurers. The new study, led by Hui-Han Chen, MHS, BS, from the UNC Eshelman School of Pharmacy at the University of North Carolina, used annual global sales in the IQVIA MIDAS® database to examine the price fluctuations after introducing biosimilars.1

“This analysis showed that the entry of biosimilars impacted the biologics price through both instant reductions and changes in long-term price trends,” wrote investigators. “Three of the eight biologics (i.e., bevacizumab, infliximab, and trastuzumab) had a significant instant reduction in price.”

Investigators aimed to assess how the introduction of biosimilars impacted the price of 8 biologic products—adalimumab, bevacizumab, epoetin, etanercept, filgrastim, infliximab, pegfilgrastim, and trastuzumab—in 57 countries and regions.

Countries and Regions

  1. Argentina
  2. Australia
  3. Austria
  4. Belarus
  5. Belgium
  6. Bosnia
  7. Brazil
  8. Bulgaria
  9. Canada
  10. Chile
  11. Colombia
  12. Croatia
  13. Egypt
  14. Estonia
  15. Finland
  16. France
  17. Germany
  18. Greece
  19. Hungary
  20. India
  21. Indonesia
  22. Ireland
  23. Italy
  24. Japan
  25. Kazakhstan
  26. Korea
  27. Latvia
  28. Lebanon
  29. Lithuania
  30. Luxembourg
  31. Malaysia
  32. Mexico
  33. Morocco
  34. Netherlands
  35. Norway
  36. Pakistan
  37. Peru
  38. Philippines
  39. Poland
  40. Portugal
  41. Romania
  42. Russia
  43. Serbia
  44. Singapore
  45. Slovakia
  46. Slovenia
  47. Spain
  48. Sweden
  49. Switzerland
  50. Taiwan
  51. Thailand
  52. Tunisia
  53. Turkey
  54. United Arab Emirates
  55. United Kingdom
  56. United States of America
  57. Vietnam

The team analyzed prices of biologic products from January 1, 2012, to December 31, 2019, using an interrupted time series design series. After biosimilar introductions, they examined the immediate and long-term changes in biologics ex-manufacturer pricing.

Investigators began by identifying the standardized dose of each biologic based on what dose appeared more frequently in the database. After that, they standardized the medicine price to the most used dosage of the biologic.

The team saw infliximab was the most available in biosimilar forms compared to the other 7 biologics. The biosimilar infliximab was available in 43 countries and regions and had a median market entry date in 2015. In contrast, bevacizumab had the lowest availability and in 2019 the biosimilar was only on the market in 7 countries.

Investigators observed an increase in consumption of both biologics and biosimilars sold each year across adalimumab, bevacizumab, epoetin, etanercept, infliximab, and pegfilgrastim. One year after biosimilars became commercially available, the total doses of biologics and biosimilars increased by 16.3% for adalimumab, 29.7% for bevacizumab, 10.8% for epoetin, 7.3% for etanercept, 6.8% for infliximab, and 7.0% for pegfilgrastim. However, the consumption of filgrastim and trastuzumab decreased by 7.2% and 3.4%, respectively.

Furthermore, they noted a lower demand for biologics with a decrease of 19.8% for adalimumab, 9.6% for epoetin, 14.8% for etanercept, 20.0% for filgrastim, 1.3% for infliximab, 13.8% for pegfilgrastim, and 17.8% for trastuzumab. The only biologic that did not have a lower demand was bevacizumab, which increased by 6.5%.

As for biosimilars sold, the proportion was 5.7% for adalimumab, 0.4% for bevacizumab, 3.0% for epoetin, 15.9% for etanercept, 15.1% for filgrastim, 13.5% for infliximab, 3.2% for pegfilgrastim, and 2.3% for trastuzumab.

Once biosimilars hit the market, a biologic product’s average price per dose dropped by $438 for trastuzumab, $112 for infliximab, and $110 for bevacizumab. Further price reductions occurred yearly, with decreases of $49 for adalimumab, $290 for filgrastim, $21 for infliximab, and $189 for trastuzumab.

Investigators also analyzed how biosimilars impacted the prices of 4 biologics in the US. They found 3 biologics in the US significantly reduced every year, reducing by $955 for filgrastim, $753 for pegfilgrastim, and $104 for infliximab.

The team outlined multiple limitations: only evaluating prices paid by wholesalers or distributors but not patients, not controlling for personal demographics like age, and not analyzing data from all countries and all biosimilars. They also noted unobserved time-variant confounders may impact the results.

“These findings not only demonstrate the economic benefits of increasing biosimilar utilization but also emphasize the importance of biosimilars in controlling healthcare costs,” investigators wrote. “Policies should aim to expand the availability of biosimilars to counteract the exponential growth of medical spending caused by the use of biologics.”


  1. Chen H-H, Yemeke T, Ozawa S (2024) Reduction of biologic pricing following biosimilar introduction: Analysis across 57 countries and regions, 2012–19. PLoS ONE 19(6): e0304851.
  2. Karaca-MandicP,ChangJ,GoR,SchondelmeyerS,WeisdorfD,JefferyMM.BiosimilarFilgrastim Uptake AndCostsAmongCommerciallyInsured,MedicareAdvantage.Healthaffairs (Project Hope). 2019; 38(11):1887–92. Epub 2019/11/05. PMID: 31682491.

Recent Videos
Dilraj Grewal, MD: Development of MNV in Eyes with Geographic Atrophy in GATHER | Image Credit: Duke Eye Center
1 KOL is featured in this series.
1 KOL is featured in this series.
1 KOL is featured in this series.
Margaret Chang, MD: Two-Year Outcomes of the PDS for Diabetic Retinopathy | Image Credit: Retina Consultants Medical Group
Phase 2 Data Shows KP1077 Meaningfully Improves Idiopathic Hypersomnia Symptoms
Carl C. Awh, MD: | Image Credit:
Raj K. Maturi, MD: 4D-150 for nAMD in PRISM Population Extension Cohort | Image Credit: Retina Partners Midwest
1 KOL is featured in this Insights series.
Charles C. Wykoff, MD, PhD: Interim Analysis on Ixo-Vec Gene Therapy for nAMD | Image Credit: Retina Consultants of Texas
© 2024 MJH Life Sciences

All rights reserved.